Targeting thymidine synthase (TS) with 5-FU or its prodrug capecitabine remains the backbone of anti-cancer therapy with its greatest impact in the prolongation of overall survival in advanced colorectal cancer (Table 1; Figure 1A) [20,38]. Here, TYMS is linked to colorectal cancer.